The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | An overview of the RADAR trial
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the actively-recruiting RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV), which aims to give newly diagnosed, transplant eligible myeloma patients access to novel therapies. Dr Ramasamy briefly explains the main aims of the RADAR trial and the number of patients that have been recruited, as well as the excitement surrounding this trial and the future treatment of multiple myeloma. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
